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ABSTRACT
Objective: The transfer of abacavir, a new nucleoside inhibitor, and amprenavir, a new protease
inhibitor, used for the treatment ofhuman immunodeficiency virus, has been studied in the ex vivo
human placental model.
Methods: The ex vivo human placental model used C14 antipyrine to determine the transport
fraction and clearance index ofthese compounds at both the peak and trough serum concentrations.
The clearance index accumulation and tissue concentrations were determined for each drug by high
pressure liquid chromatography.
Results: The clearance index of abacavir was 0.47 0.19 and 0.50 0.07 at peak and trough
concentrations, respectively. The clearance index of amprenavir was 0.38 0.09 and 0.14 0.08 at
peak and trough concentrations, respectively. There was no unusual accumulation of either drug in
the media or tissue when the perfusion system was closed.
Conclusion: Abacavir is the first nucleoside compound studied in the perfusion system with a high
clearance index. The transfer of the protease inhibitor amprenavir had a clearance index 2.75 times
greater than the clearance index of ritonavir at peak concentration determined in a previous study.
At trough concentration the clearance index was much less than at the peak concentration. A
similar result was found with ritonavir. Infect. Dis. Obstet. Gynecol. 6:244-246, 1998.
(C) 1999 Wiley-Liss, Inc.
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he number of pregnant women with human
immunodeficiency virus (HIV) worldwide con-
tinues to increase. Human immunodeficiency
virus mutates to become drug resistant very readily
in response to treatment with either single or dual
anti-HIV therapy, so aggressive therapy using
three or more anti-HIV compounds has become
necessary. This aggressive therapy requires at least
two nucleoside inhibitors and a protease inhibit
or to prevent increases in the serum RNA copy
number of the virus. Therefore, it is necessary
to have a continuous development of new anti-
viral compounds to deter these HIV-resistant
mutants.
The purpose of these experiments was to study
the new Food and Drug Administration-approved
investigational phase 3 drugs, abacavir (a nucleo-
side inhibitor) and amprenavir (a protease in-
hibitor) in the ex vivo human placental model for
transplacental passage. Both are attractive agents
for possible treatment of HIV-infected pregnant
women.
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MATERIALS AND METHODS
Investigational drugs abacavir hemisulfate
[( 1S,cis)-4-(2-amino-6-(cyclopropylamino)-9H-
purin-9-yl)-2-cyclopentane-1-methanol sulfate mw
670.7] and amprenavir [(3S)-tetrahydro-3-furylN-
(( S,2R)-3-(4-amino-N-isobutybenzenesulfamido)-
1-benzyl-2-hydropropyl)carbonate, mw 505.64]
were provided by Glaxo Wellcome (Research Tri-
angle, NC). All chemicals were purchased from
Sigma Chemical Company (St. Louis, MO).
All placentas used in this study were obtained
from normal term vaginal or cesarean section de-
liveries. This study was approved by the University
of Texas Southwestern Medical Center Institu-
tional Review Board for Human Studies. Placentas
were transported to the perfusion laboratory in a
bath of normal saline within minutes of separation
from the uterus. A suitable nontraumatized cotyle-
don was identified. The fetal artery and vein were
then cannulated with umbilical vessel catheters.
The cotyledon was then gently perfused with hep-
arinized drug-free Earles minimal essential me-
dium as previously described,z
Each placenta was then perfused with the per-
fusion media for 15-30 minutes to stabilize the. pla-
centa and remove retained blood. 14C antipyrine
(0.1 mg/mL with a specific activity of 56,600
dpm/lag) was used to determine maternal fetal
match, transport fraction (TF), and clearance index
(CI) of the antiviral drugs. 14C antipyrine was pur-
chased from ICN Biomedical (Irvine, CA). The TF
and CI were established using the formula from
Challier.3 Since antipyrine is a small molecule, a
single pass in an open perfusion system results in at
least a 40% maternal-to-fetal transfer. This is an
indication of a successful maternal-fetal match.
The maternal and fetal circulations were either
open-open, respectively, to determine TF and CI
or closed-closed to determine accumulation of the
drugs. Both the maternal and fetal systems con-
tained 150 mL of media.
The concentrations of both drugs studied in the
perfusion model were the approximate peak and
trough concentrations at a proposed maximum
single dose of 1,200 mg (Investigational Manual).
For abacavir the concentrations were 10 lag/mL and
lag/mL, and for amprenavir 7 lag/mL and 1.0
lag/mL peak and trough, respectively. At least six
studies were performed at each concentration. In
all perfusion studies approximately 2 mL of per-
fusate was collected every 5-10 minutes for one
hour for drug and C 14 antipyrine analysis.
All samples were analyzed by high pressure liq-
uid chromatography (HPLC). The HPLC instru-
mentation consisted of a 486 UV detector, WISP
auto sampler (Waters Associates, Milford, ME), 110
pump (Beckman Instruments, Houston, TX), a 10
mv recorder (Fisher Scientific), and a 300 mm x 10
mm bond-a-clone 10, C18 column (Phenomenex,
Torrance, CA). The assay for abacavir consisted of
extracting the samples with an equal volume of
acetonitrile, centrifuged at 3000g for 10 minutes,
followed by the injection of 20 laL of sample into
the HPLC. The mobile phase consisted of a buffer
consisting of 17 mL 85% phosphoric acid, 30 mL
triethylamine and 945 mL of water with the pH
adjusted to 7.2 with ammonium hydroxide. Two
hundred mL of this buffer was combined with 800
mL of methanol. The flow rate of the system was
1.0 mL/min. The UV detector was set at a wave-
length of 284 nm at a sensitivity setting of 0.01 AU.
A standard curve that breached the therapeutic
range of abacavir was prepared and extracted as
with the perfusion sample. The retention time of
the drug was about eight minutes. Within-batch
and between-batch reproducibility studies were
done on previously prepared samples that were
analyzed at least in duplicate over three days.
The HPLC method for amprenavir used the
same instrument as described above. The sample
extraction was also identical. The mobile phase
consisted of 430 mL of acetonitrile and 570 mL of
water which was filtered through a 0.45 la-millpore
filter (Millipor Corporation, Melford, MA). The
flow rate of the system was 2.0 mL/min, and the
UV detector was set at a wavelength of 270 nm.
The sensitivity of the detector was set at 0.005 AU.
A standard curve that breached the therapeutic
range of amprenavir was prepared and extracted
with the perfusate sample. Twenty microliters
were injected into the system, and the retention
time of the drug was about seven min. Within-
batch and between-batch reproducibility studies
were done on samples prepared as described pre-
viously for abacavir.
RESUI_’I’S
The within-batch and between-batch recovery
studies for both abacavir and amprenavir were
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TABLE I. Clearance index of abacavir and amprenavir
Accumulation
Drug Concentration CI + SD +/- SD
Abacavir 1.0 Isg/mL 0.47 + 0.19 0.67 + 0.10
Abacavir 10.0 Isg/mL 0.50 + 0.07 2.47 + 0.79
Amprenavir 1.3 tsg/mL 0.14 + 0.08 0.06 + 0.06
Amprenavir 6.7 Isg/mL 0.38 + 0.09 0.67 + 0.51
an= 6
SD standard deviation.
>80%, and the minimum sensitivity was -<0.1
pg/mL (data not shown). The CI and accumulation
after one hour for both abacavir and amprenavir are
depicted in Table 1.
Placental tissue samples at 1.0 pg/mL of aba-
cavir were not done. The placental tissue concen-
tration of abacavir at the therapeutic peak (10
pg/mL) was 2.38 +__ 1.25 pg/g at 10 pg/mL. The
placental tissue concentrations of amprenavir were
0.06 __+ 0.06 pg/g and 0.67 ___
0.51 pg/g at trough and
peak concentrations, respectively.
DISCUSSION
Abacavir is the first nucleoside inhibitor studied
with a high CI of about 50% that of antipyrine.
Other nucleoside inhibitors have been shown to
have a CI of 0.14 to 0.29 in our and other labora-
tories,z’4’s This suggests that abacavir is highly li-
pophilic and is readily transferred across the human
placenta by simple diffusion,z,4-6 Because the drug
readily crosses the placenta, abacavir could be clini-
cally useful in the treatment of HIV-1 in the preg-
nant patient and prevention of perinatal HIV trans-
mission.
Amprenavir crosses the placenta more readily
than ritonavir in the ex vivo placental model,z,6,7 At
trough concentrations, ritonavir was not detectable
in the fetal compartment and at peak concentra-
tion, amprenavir had a low CI, but it was approxi-
mately 2.75 times that of ritonavir.7 These data are
supported by the placental transfer of protease in-
hibitors in rabbit studies.
Although there is a larger difference in the CI of
these compounds compared with other anti-HIV
drugs studied, the clinical significance of these dif-
ferences remains unclear. Regardless of these dif-
ferences it is important to note because these drugs
readily cross the placenta; treatment of the preg-
nant patient results in exposure to the fetus. Al-
though there is a paucity of information on the use
of triple therapy in the pregnant patient, it is im-
portant that new nucleoside and protease inhibitors
are available for treatment in these patients. Since
there is a possibility that the use of three or more
drug combinations may completely suppress viral
replication, the inclusion of combination therapy in
the pregnant patient is of utmost importance. How-
ever, the short-term and long-term impact of this
aggressive therapy on the fetus and infant is un-
known.
There is also insufficient data to support or re-
fute teratogenic risk of triple antiviral therapy in
the first trimester of pregnancy. In any case, zido-
vudine should be included in any regimen, since it
is the only drug that has been shown to reduce
perinatal transmission. Regardless of the therapy
initiated, informed consent of the patient is impor-
tant, and perinatal exposure to anti-HIV therapy
should be reported to the Antiretroviral Pregnancy
Register, 800-258-4263.1
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